This study is accepting new patients by invitation only

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

a study on Graves' Disease

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
study ends around

Description

Summary

This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.

Official Title

A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease

Keywords

Graves' Disease, IMVT-1402, Immunoglobulin G, Thyroid-Stimulating Hormone Receptor, Antithyroid drug, FcRn, Graves Disease

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503.
  • Other, more specific inclusion criteria are defined in the protocol.

You CAN'T join if...

  • Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study.

Locations

  • Site Number - 1559
    San Francisco California 94143 United States
  • Site Number - 1587
    Huntington Beach California 92647 United States
  • Site Number - 1588
    Orange California 92868 United States
  • Site Number - 1554
    Los Angeles California 90033 United States
  • Site Number - 1552
    Torrance California 90509 United States
  • Site Number - 1558
    Santa Clarita California 91321 United States
  • Site Number - 1510
    Concord California 94520 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Immunovant Sciences GmbH
ID
NCT07286006
Phase
Phase 2 Graves' Disease Research Study
Study Type
Interventional
Participants
Expecting 372 study participants
Last Updated